Online citations, reference lists, and bibliographies.

The Use Of Intraperitoneal Chemotherapy For Gastric Malignancies

Antonio Macrì, Federico Morabito
Published 2019 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
ABSTRACT Introduction: Gastric cancer is the fourth/fifth most common malignancy worldwide, with only a quarter of patients achieving a 5-year survival rate. It has been estimated that 15–50% or more of patients have peritoneal disease upon surgical exploration. Until the early 1990s, peritoneal metastasis was considered as terminal stage of the disease; in the late 1990s, selected patients with peritoneal metastasis were recategorized as local disease. Over the past two decades, the treatment of peritoneal involvement has transformed, and cytoreductive surgery plus intraperitoneal therapy have drastically altered the natural course of several malignancies. Areas covered: We performed a review of studies available on PubMed from 1 January 2014 to 31 July 2019 and the analysis of their reference citations. We describe the most current intraperitoneal chemotherapy opportunities in the treatment of gastric cancer: hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC), laparoscopic hyperthermic intraperitoneal chemotherapy (LHIPEC), neoadjuvant intraperitoneal and systemic chemotherapy (NIPS), LHIPEC + NIPS, extensive intraoperative peritoneal lavage (EIPL), early postoperative intraperitoneal chemotherapy (EPIC), and pressurized intraperitoneal aerosol chemotherapy (PIPAC). Expert opinion: Comprehensive treatment consisting of CRS combined with perioperative intraperitoneal/systemic chemotherapy can, today, be considered an effective strategy to improve the long-term survival of gastric cancer patients with peritoneal metastasis.
This paper references
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Robert L. Dedrick (1978)
10.1016/S1470-2045(19)30318-3
Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications.
M. Alyami (2019)
10.3748/wjg.v20.i14.3905
Treatment options in patients with metastatic gastric cancer: current status and future perspectives.
Ahmet Erkan Bilici (2014)
10.1155/2017/4596176
Impact of Pressurized Intraperitoneal Aerosol Chemotherapy on Quality of Life and Symptoms in Patients with Peritoneal Carcinomatosis: A Retrospective Cohort Study
Hugo Teixeira Farinha (2017)
10.1016/j.soc.2018.02.012
Patient Selection for Cytoreductive Surgery.
T. Grotz (2018)
An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma.
Seishi Orii (2003)
10.5833/jjgs.45.1137
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
H. Ishigami (2009)
Peritoneal carcinomatosis 2011; it's about time for chemosurgery.
John D. Spiliotis (2011)
Cytoreductive surgery (CRS) with/without HIPEC in gastric cancer with peritoneal carcinomatosis
B ChariteUniversity (2014)
10.1245/ASO.2003.01.018
Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure and Cytoreductive Surgery for the Treatment of Peritoneal Carcinomatosis: Morbidity and Mortality Analysis of 216 Consecutive Procedures
O. Gléhen (2003)
10.1038/bjc.1995.95
Site-specific implantation in the milky spots of malignant cells in peritoneal dissemination: immunohistochemical observation in mice inoculated intraperitoneally with bromodeoxyuridine-labelled cells.
Hiroyuki Tsujimoto (1995)
Reports the first evaluation of the prophylactic role of HIPEC in gastric carcinoma
10.1002/jso.24087
Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases.
H. Shiozaki (2016)
Intraperitoneal chemo-hyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis.
A. C. Sayag-Beaujard (1999)
10.1186/s12957-016-1008-0
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Ramy Girshally (2016)
10.1002/1097-0142(19940415)73:8<2048::AID-CNCR2820730806>3.0.CO;2-Q
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
R. Hamazoe (1994)
10.1245/s10434-010-1039-7
Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy
Olivier Glehen (2010)
10.1016/j.ejso.2013.10.019
Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials.
F. Coccolini (2014)
10.1007/s00280-013-2122-0
Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis
S. Fushida (2013)
The first formal study on the role of CRS and HIPEC in the treatment of gastric cancer
10.1007/s10120-012-0182-1
Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center
Sook Hee Hong (2012)
10.1200/JCO.2002.08.105
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.
P. Ross (2002)
10.1007/s00280-007-0476-x
Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy
J. Kim (2007)
10.1245/s10434-013-3443-2
Outcome Data of Patients with Peritoneal Carcinomatosis from Gastric Origin Treated by a Strategy of Bidirectional Chemotherapy Prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in a Single Specialized Center in Japan
Emel Canbay (2014)
10.1200/JCO.18.01688
Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis.
Pierre-Emmanuel Bonnot (2019)
10.1007/s10120-003-0222-y
Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer
Hideo Baba (2003)
• Reports a systematic review of 1810 patients submitted to PIPAC, a new promising approach to peritoneal carcinomatosis
10.1016/J.EJSO.2019.03.011
Downstaging of lymph node metastasis after neoadjuvant intraperitoneal and systemic chemotherapy in gastric carcinoma with peritoneal metastasis.
Yingxia Hao (2019)
10.1007/springerreference_178671
National comprehensive cancer network.
Frank C. Detterbeck (2013)
10.4251/wjgo.v10.i10.282
Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis
Jennifer L Leiting (2018)
10.1245/s10434-017-6047-4
Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma
B. Badgwell (2017)
10.1245/s10434-016-5409-7
Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer
N. Ikoma (2016)
10.1186/s12957-016-0892-7
Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis
Manuela Robella (2016)
10.1007/s10120-010-0547-2
Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer
Shigeyuki Tamura (2010)
10.4251/wjgo.v3.i12.169
Rationale and techniques of cytoreductive surgery and peritoneal chemohyperthermia.
Antonio Macrì (2011)
[Gastric cancer].
Hernán Espejo (1996)
10.1245/s10434-013-3443-2
Outcome Data of Patients with Peritoneal Carcinomatosis from Gastric Origin Treated by a Strategy of Bidirectional Chemotherapy Prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in a Single Specialized Center in Japan
PhD Emel Canbay MD (2013)
10.3322/canjclin.49.1.33
Global cancer statistics.
D. Parkin (1999)
10.1002/jso.10190
Semi-closed hyperthermic-antiblastic peritoneal perfusion (HAPP) in the treatment of peritoneal carcinosis.
M. De Simone (2003)
10.1016/S1055-3207(03)00027-9
Management of peritoneal surface component of ovarian cancer.
Marcello Deraco (2003)
10.1159/000096002
Efficacy of S-1 for Patients with Peritoneal Metastasis of Gastric Cancer
Satoshi Ishizone (2006)
• Provides new physiopathological interpretation of peritoneal tumors, thus laying the basis for the intraperitoneal approaches
10.1016/j.ejca.2017.03.030
The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer.
Jacopo Desiderio (2017)
10.1016/S0140-6736(10)61121-X
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Y Bang (2010)
10.1016/S0959-8049(98)00375-X
Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment.
B. Berthet (1999)
10.1245/s10434-015-5081-3
Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?
Claramae Shulyn Chia (2015)
10.1007/s13193-019-00893-x
History of Peritoneal Surface Malignancy Treatment in Japan
Yutaka Yonemura (2019)
10.4143/crt.2014.46.3.270
Early Postoperative Intraperitoneal Chemotherapy for Macroscopically Serosa-Invading Gastric Cancer Patients
Oh Kyoung Kwon (2014)
10.1152/ajprenal.00313.2004
The transport barrier in intraperitoneal therapy.
M. Flessner (2005)
10.1002/jso.22057
Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination.
Y. Fujiwara (2012)
10.1245/s10434-016-5487-6
Effects of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy and Neoadjuvant Intraperitoneal/Systemic Chemotherapy on Peritoneal Metastases from Gastric Cancer
Yutaka Yonemura (2016)
10.1016/j.ejso.2015.03.231
Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis.
F. Coccolini (2015)
10.1200/JCO.2018.36.4_SUPPL.8
CYTO-CHIP: Cytoreductive surgery versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: A propensity-score analysis from BIG RENAPE and FREGAT working groups.
Pierre Emmanuel Bonnot (2018)
• GASTRICHIP is the most recent RCT in this field
10.1016/j.ejso.2018.06.036
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis.
Cristina Rihuete Caro (2018)
Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers
10.1093/jjco/hyt114
Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).
K. Shirao (2013)
10.1200/JCO.2006.06.8429
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
E. Van Cutsem (2006)
Quality of life of patients with end-stageperitoneal metastasis treated with Pressurized IntraPeritonealAerosol Chemotherapy (PIPAC)
K Odendahl (2015)
10.1245/s10434-011-1631-5
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial
Xiaojun Yang (2011)
10.1007/978-1-4613-1247-5_6
Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology.
P. Sugarbaker (1996)
10.1186/1471-2407-14-148
Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab
D. Goéré (2013)
10.1111/j.1525-1438.2003.13319.x
Long‐term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum
M. Look (2003)
10.1200/JCO.1989.7.9.1310
Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer.
P. Preusser (1989)
10.1016/S0039-6060(96)80145-0
Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination.
Y. Yonemura (1996)
10.1007/s10120-011-0071-z
A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer
Pierre-Anthony Leake (2011)
10.1007/s11912-018-0703-0
Peritoneal Metastases from Gastrointestinal Cancer
Paul H Sugarbaker (2018)
10.1245/ASO.2005.03.065
The Value of Peritoneal Cytology as a Preoperative Predictor in Patients With Gastric Carcinoma Undergoing a Curative Resection
David J Bentrem (2005)
10.1097/SLA.0b013e3181b0c80e
Extensive Intraoperative Peritoneal Lavage as a Standard Prophylactic Strategy for Peritoneal Recurrence in Patients with Gastric Carcinoma
Masafumi Kuramoto (2009)
10.1007/s13193-011-0074-6
Positive Peritoneal Cytology in Patients with Gastric Cancer: Natural History and Outcome of 291 Patients
J. Mezhir (2011)
10.1245/s10434-011-1770-8
Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer Patients with Peritoneal Dissemination
Y. Fujiwara (2011)
10.1093/annonc/mdf019
Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.
Dominique M Elias (2002)
10.1016/j.soc.2018.02.006
Evolving Treatment Strategies and Outcomes in Advanced Gastric Cancer with Peritoneal Metastasis.
Fadi Dahdaleh (2018)
10.1007/BF00319049
Cellular subsets of the milky spots in the human greater omentum
Masataka Shimotsuma (1991)
10.1016/S1470-2045(03)01074-X
Intraperitoneal antineoplastic drug delivery: rationale and results.
Maurie Markman (2003)
10.1097/DCR.0000000000001003
Prior Surgical Score: An Analysis of the Prognostic Significance of an Initial Nondefinitive Surgical Intervention in Patients With Peritoneal Carcinomatosis of a Colorectal Origin Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy
B K Paul (2018)
10.1093/annonc/mdt401
No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy.
N. Bernards (2013)
10.1002/(SICI)1097-0142(19970301)79:5<884::AID-CNCR3>3.0.CO;2-C
Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery.
S. Fujimoto (1997)
10.1093/annonc/mdn717
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Y. Kang (2009)
10.1007/s00259-010-1639-2
177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi
Christof Seidl (2010)
10.1186/s12885-016-2668-4
Dynamic changes of tumor gene expression during repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with peritoneal cancer
Günther A Rezniczek (2016)
The role of prophylactic hyperthermic intraperitoneal chemotherapy in the management of serosal involved gastric cancer.
Edoardo Saladino (2014)
10.1245/s10434-013-3213-1
Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy
W. Solass (2013)
10.1016/j.jamcollsurg.2006.12.048
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures.
E. Levine (2007)
10.1056/NEJMoa073149
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
D. Cunningham (2008)
10.1016/S1055-3207(03)00037-1
Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma.
Olivier Glehen (2003)
10.1016/j.gassur.2003.12.014
Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer
Jason John Hall (2004)
Stomach cancer estimated incidence, mortality and prevalence, worldwide. GLOBOCAN. International Association of Cancer Registries
(2012)
Atlas and principles of peritonectomy for peritoneal surface malignancy. Published by NPO to Support Peritoneal Surface Malignancy
editor (2012)
10.1002/ijc.28373
Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors.
Irene Thomassen (2014)
10.1007/978-0-387-48993-3_2
Molecular biology of peritoneal carcinomatosis.
David G. Jayne (2007)
10.1177/1758835918777036
Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis
Martin Graversen (2018)
10.1023/A:1008243606668
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
B. Glimelius (1997)
10.1007/s11605-015-2995-9
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis
G. Nadiradze (2015)
10.1002/jso.21059
The Delphi approach to Attain consensus in methodology of local regional therapy for peritoneal surface malignancy.
Shigeki Kusamura (2008)
Lymph flow mechanism of the subperitoneal diaphragmatic lymphatics.
Ulrich Bettendorf (1978)
10.1515/pp-2016-0017
Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2)
Vladimir Khomyakov (2016)
10.1002/cncr.28204
A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
H. Yamaguchi (2013)
10.1016/S0140-6736(86)91510-2
RECURRENCE AND SURVIVAL AFTER TOTAL MESORECTAL EXCISION FOR RECTAL CANCER
Richard Heald (1986)
An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma.
Marcello Deraco (2003)
10.1186/1471-2407-14-183
GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study
Olivier Glehen (2013)
10.1001/archsurg.139.1.20
Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer.
O. Glehen (2004)
10.1245/s10434-016-5757-3
Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer
Linda M. Pak (2016)
10.1186/1471-2407-12-526
Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials
Jingxu Sun (2012)
10.1038/bjc.1995.114
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
S. Pyrhönen (1995)
10.1097/01.sla.0000143245.28656.15
Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma
Michael D'Angelica (2004)
10.1002/ijc.25423
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
Markus Maria Heiss (2010)
10.1016/j.ejso.2017.09.010
Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis.
M. Alyami (2017)
10.1016/j.ejso.2015.06.001
Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).
K. Odendahl (2015)
10.1016/j.ejso.2016.03.016
A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent.
Y. Yonemura (2016)
10.1007/s10120-014-0423-6
A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer
C. Bokemeyer (2014)
10.4251/wjgo.v2.i2.85
Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer.
Yutaka Yonemura (2010)
10.1007/978-1-4613-1247-5_4
Peritoneal-plasma barrier.
P. Jacquet (1996)
10.1016/j.ejso.2006.03.007
Neoadjuvant treatment of gastric cancer with peritoneal dissemination.
Y. Yonemura (2006)
10.1200/JCO.2004.08.154
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.
I. Chau (2004)
10.1007/s10434-999-0790-0
Morbidity and Mortality Analysis of 200 Treatments With Cytoreductive Surgery and Hyperthermic Intraoperative Intraperitoneal Chemotherapy Using the Coliseum Technique
A. D. Stephens (1999)
10.1016/S1470-2045(08)70035-4
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Wasaburo Koizumi (2008)
10.1016/S1470-2045(13)70102-5
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Florian Lordick (2013)
Tissue concentration of platinum after intraperitoneal cisplatinum in patients (PTS)
JG McVie (1985)
10.1136/bmj.1.5450.1567
Epidemiology of Stomach Cancer
Takeshi Thomas Hirayama (1968)
10.4172/2161-069X.S12-007
Trans-Lymphatic Metastasis in Peritoneal Dissemination
Yutaka Yonemura (2013)
10.1002/1097-0142(19880115)61:2<232::AID-CNCR2820610205>3.0.CO;2-U
Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C.
S. Koga (1988)
10.1007/s10120-011-0085-6
Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry
Y. Isobe (2011)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar